Pharmacokinetic Drug Interaction Study of Dapagliflozin and Glimepiride or Sitagliptin in Healthy Subjects

Completed · Phase 1

Conditions studied: Type 2 Diabetes Mellitus

In brief

To assess the effect of glimepiride on the PK of dapagliflozin and the effect of dapagliflozin on the PK of glimepiride, when co-administered in healthy subjects (Phase A) and to assess the effect of sitagliptin on the PK of dapagliflozin and the effect of dapagliflozin on the PK of sitagliptin, when co-administered in healthy subjects (Phase B)

Key facts

Study ID

NCT00842556

Run by

AstraZeneca

People needed

18

Starts

2009-03-01

Expected to finish

2009-05-01

Last updated by the study team

2016-10-17

Who can join

Age: 18 and older, up to 45. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations
• Body mass index (BMI) of 18 to 32 kg/m2, inclusive BMI = weight (kg)/[height(m)]2

You may not qualify if…

• WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 12 weeks after the last dose of investigational product
• Abnormal liver functions tests (ALT, AST or total bilirubin > 10% above ULN)
• History of chronic or recurrent UTI (defined as 3 occurrences per year) or UTI in the past 3 months
• History of allergy to SGLT@ inhibitors, DPP$ inhibitors or sulfonylurea or related compounds
• Prior exposure to dapagliflozin, sitagliptin and glimepiride within 3 months of Day -1
• History of recurrent (defined as 3 occurrences per year) or recent vulvovaginal mycotic infections

Where it is running

• Ppd Development — Austin, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.